Share on LinkedInShare on LinkedIn

ARTICLE · 04 DECEMBER 2017

Eleventh Circuit Affirms Preemption Of HRT Complaint

Today is the birthday of Gilbert O'Sullivan, who scored a hit back in 1972 with "Alone Again, Naturally," the saddest song we can think of this side of Albinoni's Adagio. That is fitting, given our postscript.

United StatesLitigation, Mediation & Arbitration

Today is the birthday of Gilbert O'Sullivan, who scored a hit back in 1972 with "Alone Again, Naturally," the saddest song we can think of this side of Albinoni's Adagio.  That is fitting, given our postscript.

December 1 is also the birthday of Sarah Silverman and Bette Midler, two women who consistently bring smiles, so we'll discuss a good case out of the Eleventh Circuit, though probably not good enough to crack our upcoming top ten list.  In Tsavaris v. Pfizer, Inc., 2017 WL 5593488 (11th Cir. Nov. 21, 2017), the plaintiff claimed that she developed breast cancer after ingesting a generic version of a hormone replacement drug.  She sued both the brand and generic manufacturers.  We don't know what happened regarding the brand manufacturer (they should certainly have secured a dismissal), but we know that the district court dismissed the claims against the generic manufacturer on preemption grounds well-established in the Mensing and Bartlett SCOTUS decisions

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from